Comparison of aprepitant combination regimen with 4-day ondansetron + 4-day dexamethasone for prevention of acute and delayed nausea/vomiting after cisplatin chemotherapy

Aapro, Matti; Schmoll, Hans Joachim; Poli-Bigelli, S.; Jordan, Karin; Pawel, Joachim von; Giezek, Hilde; Ahmed, Tuli; Chan, Christina Y.

doi:10.1200/jco.2005.23.16_suppl.8007

Cited by 4 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a commonly used and recommended antiemetic regimen is to treat patients with a combination of a 5-HT3 receptor antagonist and a corticosteroid for multiple days. Aapro et al presented a study at the annual ASCO 2005 meeting in which the aprepitant regimen was compared with a multiple-day ondansetron regimen similar to that used in clinical practice in patients receiving their first cycle of cisplatin (≥ 70 mg/m 2 ) [18]. In this study, group I received aprepitant 125 mg + dex- …”

Section: Highly Emetogenic Chemotherapymentioning

confidence: 99%

Neurokinin-1-Receptor Antagonists: A New Approach in Antiemetic Therapy

Jordan

2006

Oncol Res Treat

View full text Add to dashboard Cite

Aprepitant (Emend®), the first neurokinin-1-receptor antagonist (NK-1-RA), represents a new class of antiemetics. Aprepitant has been approved for the prevention and treatment of acute (0-24 h after chemotherapy) and delayed (1-5 days after chemotherapy) emesis resulting from cisplatin-based chemotherapy and moderately emetogenic chemotherapy. The addition of aprepitant to standard antiemetic therapy in cisplatin-based chemotherapy significantly improves emesis protection in general and, in particular, in the delayed phase by approximately 20%. Results from a recently published study in patients receiving moderately emetogenic chemotherapy suggest a benefit of aprepitant when combined with dexamethasone and a 5-HT3 receptor antagonist for the prevention of acute emesis, followed by aprepitant as a single agent in the prevention of delayed emesis. Altogether, the addition of aprepitant to the standard antiemetic regimen (5-HT3 receptor antagonist and dexamethasone) significantly improves the protection against vomiting in the acute as well as in the delayed phase in highly and moderately emetogenic chemotherapies. Therefore, the combination of a 5-HT3 receptor antagonist, dexamethasone and aprepitant should be considered as a new standard antiemetic therapy.

show abstract

Section: Highly Emetogenic Chemotherapymentioning

confidence: 99%

Neurokinin-1-Receptor Antagonists: A New Approach in Antiemetic Therapy

Jordan

2006

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

“…The development of 5HT3 antagonists (granisetron, tropisetron and ondansetron) has been a major step forward in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) [2]. These agents have been widely regarded as the most efficacious anti-emetics available today and have been recommended for several years, often in combination with corticosteroids, as the agents of first choice to control nausea and vomiting in most instances [3].…”

mentioning

confidence: 99%

“…In addition, these symptoms will increase health care resource utilisation and costs due to additional drug treatments, physician visits, etc. [5,3]. Aprepitant, a novel neurokinin-1 (NK-1) antagonist, has been recently introduced as a new class of drugs available to prevent CINV.…”

mentioning

confidence: 99%

Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium

Annemans

Strens²,

Lox

et al. 2007

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…In a follow-up study to the two randomised studies described above, the aprepitant regimen was shown to have a higher CR in patients receiving cisplatin not only to the 1-day ondansetron and 4-day dexamethasone regimen in the previous trials, but also to a 4-day ondansetron and 4-day dexamethasone regimen [55].…”

Section: Substance P (Neurokinin-1) Receptor Antagonistsmentioning

confidence: 95%

“…The antiemetic activity of aprepitant also appeared to be enhanced by combination with either dexamethasone or the 5-HT 3 receptor antagonist ondansetron. These animal studies have recently led to Phase II/III studies of NK-1 receptor antagonists in humans [43][44][45][46][47][48][49][50][51][52]55,56].…”

Section: Substance P (Neurokinin-1) Receptor Antagonistsmentioning

confidence: 99%

Emerging drugs for chemotherapy-induced emesis

Navari

Province

2006

Expert Opinion on Emerging Drugs

View full text Add to dashboard Cite

Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life. The emetogenicity of the chemotherapeutic agents, repeated chemotherapy cycles and patient risk factors (female gender, younger age, no alcohol consumption, history of motion sickness) are the major risk factors for CINV. The use of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists plus dexamethasone has significantly improved the control of acute CINV, but delayed nausea and vomiting remains a significant clinical problem. Two new agents, palonosetron and aprepitant, have recently been approved for the prevention of both acute and delayed CINV. Palonosetron is a 5-HT3 receptor antagonist with a longer half-life and a higher binding affinity than first-generation 5-HT3 receptor antagonists. Aprepitant is the first agent available in the new drug class of neurokinin-1 receptor (NK-1) antagonists. There are a number of 5-HT3 receptor antagonists and NK-1 receptor antagonists currently in Phase II and III clinical trials. Revised antiemetic guidelines for the prevention of CINV are reviewed. Future studies may consider the use of palonosetron and aprepitant with current and other new agents (olanzapine, gabapentin) in moderately and highly emetogenic chemotherapy, as well as in the clinical settings of multiple-day chemotherapy and bone marrow transplantation.

show abstract

Comparison of aprepitant combination regimen with 4-day ondansetron + 4-day dexamethasone for prevention of acute and delayed nausea/vomiting after cisplatin chemotherapy

Cited by 4 publications

References 0 publications

Neurokinin-1-Receptor Antagonists: A New Approach in Antiemetic Therapy

Neurokinin-1-Receptor Antagonists: A New Approach in Antiemetic Therapy

Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium

Emerging drugs for chemotherapy-induced emesis

Contact Info

Product

Resources

About